Revolution Medicines (RVMD) to Release Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is expected to be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Revolution Medicines to post earnings of ($2.04) per share and revenue of $1.7730 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the previous year, the firm posted ($1.13) EPS. On average, analysts expect Revolution Medicines to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Revolution Medicines Stock Down 2.7%

Shares of NASDAQ:RVMD opened at $182.45 on Tuesday. The stock has a market cap of $38.79 billion, a P/E ratio of -25.81 and a beta of 1.39. The firm has a fifty day moving average price of $173.19 and a 200 day moving average price of $135.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. Revolution Medicines has a 1-year low of $34.00 and a 1-year high of $194.56.

Analysts Set New Price Targets

A number of brokerages have recently commented on RVMD. Wedbush upped their target price on shares of Revolution Medicines from $181.00 to $192.10 and gave the company an “outperform” rating in a report on Thursday, July 23rd. Guggenheim raised their price target on Revolution Medicines from $205.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Evercore restated an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Sanford C. Bernstein started coverage on Revolution Medicines in a research note on Thursday, May 21st. They set a “market perform” rating and a $151.00 price objective for the company. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $144.67.

Insider Buying and Selling at Revolution Medicines

In other news, CFO Jack Anders sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the completion of the transaction, the chief financial officer directly owned 123,269 shares of the company’s stock, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Margaret A. Horn sold 60,400 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the completion of the sale, the chief operating officer directly owned 158,222 shares of the company’s stock, valued at $25,342,417.74. This represents a 27.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 132,497 shares of company stock valued at $21,470,486. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nextech Invest Ltd. grew its stake in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after purchasing an additional 1,304,347 shares during the period. Millennium Management LLC boosted its holdings in Revolution Medicines by 681.8% during the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock worth $5,529,000 after buying an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Revolution Medicines by 14.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after buying an additional 37,345 shares during the period. Invesco Ltd. grew its position in Revolution Medicines by 19.3% during the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after buying an additional 36,760 shares during the period. Finally, Jump Financial LLC lifted its position in shares of Revolution Medicines by 87.9% during the 2nd quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock valued at $561,000 after acquiring an additional 7,137 shares during the period. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.